ACTiVION-II, the first of two US Phase 3 clinical trials, did not meet co-primary endpoints of VAS pain score and WOMAC® total score at Month 12Results from ACTiVION-I, the second Phase 3 trial of ...

After a single intravitreal dose of 4D-150, visual acuity and anatomic control was maintained with consistent and durable treatment burden reduction through 2 years 4D-150 continues to be well tolerat ...

Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the "Company"), a development-stage biotechnology company developing new medicines to treat pain and neuropathy, ...

TheFly reported on June 30 that VTGN announced topline findings from the PALISADE-4 Phase 3 trial evaluating intranasal ...

TheFly reported on June 30 that Canaccord reduced its price target on DFTX to $58 from $60 while reaffirming a Buy rating on ...

Continued low early termination rate (4.5%) among the first 200 patients enrolled in the study suggests Halneuron® and ...

Three months. That’s how long the entire trial took in a patent dispute before the Delhi High Court.The Communication ...

Immunomic Therapeutics, Inc. (ITI), a clinical-stage biotechnology company and a U.S.-based subsidiary of HLB, today announced that the first participant has been dosed in the Phase 1 clinical trial ...

The trial of Anne Marie Baker, the 58-year-old Centralia woman accused of embezzling $1.4 million from a former employer over a seven-year period, has been pushed to at least Sept. 28. A ...

CAMBRIDGE, MA / ACCESS Newswire / July 16, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced the dosing of the first ...

Shanghai Stock Exchange listed company HitGen Inc. ("HitGen", SSE: 688222.SH), congratulates its partner BioAge Labs, Inc.

Background and aims Restoration of intestinal barrier integrity and function in inflammatory bowel disease (IBD) has been ...